Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-CPPC
- Development stage
- Phase 2
- Lead developer
- Johns Hopkins University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
**11C-CPPC** is a positron-emitting radiotracer developed for use in positron emission tomography (PET) imaging. It selectively binds to the colony-stimulating factor 1 receptor (CSF1R), which is predominantly expressed on microglial cells in the brain. By targeting CSF1R, 11C-CPPC enables non-invasive imaging of microglial activation and neuroinflammation in vivo. This radiotracer has demonstrated high affinity and selectivity for CSF1R (IC50 values as low as 0.8 nM), making it suitable for studying neuroimmune processes associated with diseases such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and post acute COVID‑19 syndrome ("Long COVID"). Its primary application is as a diagnostic tool to visualize and quantify microglial activity in neurological disorders using PET scans[3][6][8].
- Other names
- 5-cyano-N-(4-(4-[11C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on 11C-CPPC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11C-CPPC.